GlassScriptPhysician profile
Cristina Vo
NPI 1972034460
$3,850.25
in general payments reported to CMS, 2019-2025
20 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $1,412 · 2024: $1,025 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,741 · Education: $0.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,741.19 |
| Education | $0.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,110.00 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $766.96 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $446.99 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $282.10 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $264.37 | 2023-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $218.34 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.51 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Optinose US, INC. | $102.41 | 2023-2025 | |
| Amgen INC. | $97.48 | 2025 | Tezspire |
| Pfizer INC. | $94.67 | 2023-2024 | |
| Csl Behring | $45.24 | 2025 | Andembry, Hizentra |
| Kaleo, INC. | $41.15 | 2024 | Auvi-Q |
| Phadia US INC. | $39.87 | 2024 | Immunocap |
| Covis Pharma Gmbh | $33.21 | 2022 | |
| Biocryst US Sales Co., LLC | $30.84 | 2024 | Orladeyo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $26.88 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.83 | 2023 | Spiriva Respimat |
| Pharming Healthcare, INC. | $24.52 | 2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $23.58 | 2025 | Donidalorsen |
| Hikma Pharmaceuticals USA | $13.30 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.